APA (7th ed.) Citation

O, O., V, Z., F, S., D, V., P, Y., C, T., . . . S, P. (2022). A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin. ClinicoEconomics and outcomes research : CEOR, 14, 119. https://doi.org/10.2147/CEOR.S340290

Chicago Style (17th ed.) Citation

O, Olatoke, Zah V, Stanicic F, Vukicevic D, Yfantopoulos P, Thompson C, DeGeorge MK, and Passik S. "A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin." ClinicoEconomics and Outcomes Research : CEOR 14 (2022): 119. https://doi.org/10.2147/CEOR.S340290.

MLA (9th ed.) Citation

O, Olatoke, et al. "A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin." ClinicoEconomics and Outcomes Research : CEOR, vol. 14, 2022, p. 119, https://doi.org/10.2147/CEOR.S340290.